GS002 / Shanghai Ginspire Biologics - LARVOL DELTA

GS002, a novel anti-PD-L1 ADC with targeted cytotoxic delivery and immune checkpoint inhibition (AACR 2026) - "Furthermore, its developability profile was comparable to the unconjugated antibody (002mAb), showing similar hydrophobicity and thermostability as evidenced by identical HIC retention times and closely matched Tm and Tagg values. In summary, GS002 represents a highly differentiated PD-L1-targeting ADC candidate with synergistic dual mechanisms, compelling efficacy in vitro and in vivo, a favorable pharmacokinetic profile, and excellent developability properties, supporting its advancement into further IND-enabling development."

ADC • Checkpoint inhibition • Oncology